New transplant drug under Real-World watch in korea
NCT ID NCT06555432
Summary
This study is monitoring the safety and effectiveness of the approved drug LIVTENCITY (maribavir) when used in routine medical practice. It will follow 168 adults in South Korea who have a difficult-to-treat CMV infection after an organ or stem cell transplant. The goal is to collect real-world information on side effects and how well the drug works over about 5 months of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Seoul ST. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.